Multivariate modelling to study the effect of the manufacturing process on the complete tablet dissolution profile.

Dissolution is invariably identified as a critical quality attribute for oral solid dosage forms, since it is related to when a drug is available for absorption and ultimately exert its effect. In this paper, the influence of granule and compression variability introduced by a design of experiments on the entire dissolution profile was studied with an innovative multivariate tool: bi-directional projections to orthogonal structures (O2PLS). This method enabled a more holistic process understanding compared to conventional approaches where only a single response is used to quantify dissolution. The O2PLS analysis of tablet manufacturing data showed that the disintegration phase of dissolution (10-15 min) was controlled by granule attributes and tablet hardness, while the later phase (15-30 min) was solely controlled by granule attributes. The bidirectional nature of the O2PLS model made it more fit for exploratory purposes, but decreased predictive ability. This approach does not require prior knowledge on the dissolution mechanism and is therefore particularly suited for exploratory studies gaining process understanding during early phase development. The outcome can then guide the selection of attributes, parameters and their ranges for the development of predictive models, e.g., models to define a suitable design space for the process.

[1]  Pedro Hernandez-Abad,et al.  Quality by design case study: an integrated multivariate approach to drug product and process development. , 2009, International journal of pharmaceutics.

[2]  S. Wold,et al.  Orthogonal projections to latent structures (O‐PLS) , 2002 .

[3]  Bernd Schmidt,et al.  The OPLS methodology for analysis of multi‐block batch process data , 2006 .

[4]  Theodora Kourti,et al.  Pharmaceutical Manufacturing: The Role of Multivariate Analysis in Design Space, Control Strategy, Process Understanding, Troubleshooting, and Optimization , 2010 .

[5]  Theodora Kourti,et al.  Troubleshooting of an Industrial Batch Process Using Multivariate Methods , 2003 .

[6]  Shashank Jain QUALITY BY DESIGN (QBD): A COMPREHENSIVE UNDERSTANDING OF IMPLEMENTATION AND CHALLENGES IN PHARMACEUTICALS DEVELOPMENT , 2014 .

[7]  Salvador García-Muñoz,et al.  A framework for in-silico formulation design using multivariate latent variable regression methods. , 2011, International journal of pharmaceutics.

[8]  Stéphanie Dagron,et al.  Die International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) , 2014 .

[9]  Theodora Kourti,et al.  Process Analytical Technology Beyond Real-Time Analyzers: The Role of Multivariate Analysis , 2006 .

[10]  Chris Potter,et al.  PQLI Application of Science- and Risk-based Approaches (ICH Q8, Q9, and Q10) to Existing Products , 2009, Journal of Pharmaceutical Innovation.

[11]  Johan Trygg,et al.  O2‐PLS, a two‐block (X–Y) latent variable regression (LVR) method with an integral OSC filter , 2003 .

[12]  Emad B. Basalious,et al.  Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants and Crystallization Inhibitors: Development of Controlled-Release Tablets , 2011, AAPS PharmSciTech.

[13]  Raymond H. Myers,et al.  Response Surface Methodology--Current Status and Future Directions , 1999 .

[14]  J. Abraham The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .

[15]  Johanna Smeyers-Verbeke,et al.  Handbook of Chemometrics and Qualimetrics: Part A , 1997 .

[16]  Carlo Castagnoli,et al.  Application of Quality by Design Principles for the Definition of a Robust Crystallization Process for Casopitant Mesylate , 2010 .

[17]  Nils-Olof Lindberg,et al.  Multivariate methods in pharmaceutical applications , 2002 .

[18]  J. Trygg,et al.  Combining experimental design and orthogonal projections to latent structures to study the influence of microcrystalline cellulose properties on roll compaction. , 2011, International journal of pharmaceutics.

[19]  John J. Peterson,et al.  The ICH Q8 Definition of Design Space: A Comparison of the Overlapping Means and the Bayesian Predictive Approaches , 2010 .

[20]  Russ Somma,et al.  Development Knowledge Can Increase Manufacturing Capability and Facilitate Quality by Design , 2007, Journal of Pharmaceutical Innovation.

[21]  Pierantonio Facco,et al.  Latent variable modeling to assist the implementation of Quality-by-Design paradigms in pharmaceutical development and manufacturing: a review. , 2013, International journal of pharmaceutics.

[22]  James K. Drennen,et al.  Risk-based Quality by Design (QbD): A Taguchi Perspective on the Assessment of Product Quality, and the Quantitative Linkage of Drug Product Parameters and Clinical Performance , 2008, Journal of Pharmaceutical Innovation.

[23]  Matrix tablets containing HPMC and polyamide 12 : comparison of dissolution data using the Gompertz function , 1994 .

[24]  Mark Reynolds,et al.  Interdependence of drug substance physical properties and corresponding quality control strategy. , 2012, Journal of pharmaceutical sciences.

[25]  San Kiang,et al.  Can pharmaceutical process development become high tech , 2006 .